Alpha 2.0
Login Register
» Articles » PMID: 15140620

Effector Mechanisms in Anti-MAG Antibody-mediated and Other Demyelinating Neuropathies

Overview
Journal J Neurol Sci
Publisher Elsevier
Specialty Neurology
Date 2004 May 14
PMID 15140620
Citations 6
Authors
Norman Latov
Susanne Renaud
Affiliations
Soon will be listed here.
Citing Articles

Anti-MAG neuropathy: historical aspects, clinical-pathological correlations, and considerations for future therapeutical trials.

Latov N, Brannagan 3rd T, W Sander H, de Assis Aquino Gondim F Arq Neuropsiquiatr. 2024; 82(6):1-7.

PMID: 38325389 PMC: 10849826. DOI: 10.1055/s-0043-1777728.

Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies.

Dalakas M Ther Adv Neurol Disord. 2018; 11:1756285617746640.

PMID: 29403542 PMC: 5791554. DOI: 10.1177/1756285617746640.

GSK249320, A Monoclonal Antibody Against the Axon Outgrowth Inhibition Molecule Myelin-Associated Glycoprotein, Improves Outcome of Rodents with Experimental Stroke.

Cash D, Easton A, Mesquita M, Beech J, Williams S, Lloyd A J Neurol Exp Neurosci. 2016; 2(2):28-33.

PMID: 28018988 PMC: 5179224.

Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy.

Leger J, Viala K, Nicolas G, Creange A, Vallat J, Pouget J Neurology. 2013; 80(24):2217-25.

PMID: 23667063 PMC: 3721095. DOI: 10.1212/WNL.0b013e318296e92b.

Treatment with rituximab in patients with polyneuropathy with anti-MAG antibodies.

Delmont E, Jeandel P, Benaim C, Rosenthal E, Fuzibet J, Desnuelle C J Neurol. 2011; 258(9):1717-9.

PMID: 21437663 DOI: 10.1007/s00415-011-5994-0.